Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated